The lnc<scp>RNA HNF</scp>1A‐<scp>AS</scp>1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma

Lijun Cai, Jinhan Lv, Yinquan Zhang, Junhong Li, Yinong Wang, Huilin Yang

Journal of Cellular and Molecular Medicine · 2017 · 58 citations · 20 references

DOIFull text

Open access

Concepts

Abstract

Abstract Recent studies have revealed that long noncoding RNA HNF 1A‐antisense 1 ( HNF 1A‐ AS 1) plays an important role in the development of several human malignancy entities. However, the expression and function of HNF 1A‐ AS 1 in the carcinogenesis and development of osteosarcoma remains unknown. In this study, we detected the HNF 1A‐ AS 1 levels in human osteosarcoma tissues and cell lines by quantitative real‐time polymerase chain reaction ( qRT ‐ PCR ), and investigated its role in osteosarcoma by using in vitro assays. Our study showed that HNF 1A‐ AS 1 expression was significantly up‐regulated in human osteosarcoma tissues and cell lines compared with their normal counterparts, and its expression level was positively correlated with the distance metastasis ( P = 0.009) and tumour stage ( P = 0.019). Moreover, Kaplan–Meier curves with the log‐rank test showed that higher expression of HNF 1A‐ AS 1 conferred a significantly poorer survival and multivariate Cox proportional hazards analysis revealed that HNF 1A‐ AS 1 was an independent risk factor of overall survival. In addition, the expression of HNF 1A‐ AS 1 in serum is correlated with patients’ status and receiver operating characteristic ( ROC ) curve analysis demonstrated that HNF 1A‐ AS 1 could distinguish patients with osteosarcoma from healthy individuals (the area under curve 0.849, P &lt; 0.001). Furthermore, in vitro knockdown of HNF 1A‐ AS 1 by si RNA significantly inhibited cell proliferation and G 1 /S transition, and suppressed migration and invasion by reducing the epithelial‐mesenchymal transition ( EMT ) program in osteosarcoma cells. Taken together, our data suggested that HNF 1A‐ AS 1 is a novel molecule involved in osteosarcoma progression, which may provide as a potential diagnostic, prognostic biomarker and therapeutic target.

References

20